ONCY (Oncolytics Biotech) Other Current Receivables: $0.96 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ONCY Oncolytics Biotech Inc ONCY
28 GF Score
Price $0.83
! 2 Warning Signs
View Full Analysis

What is Oncolytics Biotech Other Current Receivables?

Oncolytics Biotech ONCY -2.19% 28 Other Current Receivables is $0.96 Mil as of Mar. 2026. GuruFocus rates ONCY with a GF Score™ of 28/100. The stock has 2 warning signs investors should review.

Oncolytics Biotech's Other Current Receivables for the quarter that ended in Mar. 2026 was $0.96 Mil.

Oncolytics Biotech's quarterly Other Current Receivables increased from Sep. 2025 ($0.04 Mil) to Dec. 2025 ($0.57 Mil) and increased from Dec. 2025 ($0.57 Mil) to Mar. 2026 ($0.96 Mil).

Oncolytics Biotech's annual Other Current Receivables increased from Dec. 2023 ($0.01 Mil) to Dec. 2024 ($0.05 Mil) and increased from Dec. 2024 ($0.05 Mil) to Dec. 2025 ($0.57 Mil).

Oncolytics Biotech Other Current Receivables Related Terms

Oncolytics Biotech Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Oncolytics Biotech's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncolytics Biotech Other Current Receivables Chart

Oncolytics Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.68 0.38 0.01 0.05 0.57

Oncolytics Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.05 0.04 0.57 0.96
ONCY
28GF Score
Oncolytics Biotech Inc ONCY
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncolytics Biotech Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of $0.96 Mil mean?
Oncolytics Biotech (ONCY) has a Other Current Receivables of $0.96 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Oncolytics Biotech and its competitors.
Is Oncolytics Biotech's Other Current Receivables too high?
Oncolytics Biotech's current Other Current Receivables is $0.96 Mil. Overall, Oncolytics Biotech has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Oncolytics Biotech's Other Current Receivables compare to VRCA and ENGN?
Oncolytics Biotech's Other Current Receivables of $0.96 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Oncolytics Biotech and its competitors. Oncolytics Biotech's current Other Current Receivables is $0.96 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncolytics Biotech stock overvalued right now?
Oncolytics Biotech (ONCY) has a current Other Current Receivables of $0.96 Mil. The current Other Current Receivables is $0.96 Mil. Oncolytics Biotech's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Oncolytics Biotech (ONCY), the current Other Current Receivables is $0.96 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oncolytics Biotech Business Description

Address 4350 Executive Drive, Suite 325, San Diego, CA, USA, 92121
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.
28GF Score

Get the complete analysis for ONCY

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.83
Price